动脉瘤性蛛网膜下腔出血早期脑损伤的临床结局预测:SHELTER评分
本研究为回顾性分析,纳入2014年1月至2022年9月单中心连续收治的561例动脉瘤性蛛网膜下腔出血(aSAH)患者,分析出血后72小时内的14项潜在预测因子,以6个月改良Rankin量表(mRS)三分类(0-2分良好、3-5分不良、6分死亡)为结局,构建SHELTER评分。评分包含年龄、世界神经外科医师联盟评分、心肺复苏、瞳孔散大、中线移位、早期恶化、早期缺血性病灶共7项,McFadden伪R²=0.339,死亡或残疾的曲线下面积为0.899,死亡的曲线下面积为0.877。SHELTER评分低于5分提示良好结局,5至6.5分预测不良结局,≥7分与6个月死亡相关。作者认为该评分有助于神经重症医生识别不良结局患者并指导治疗决策。
要点
- SHELTER评分由7项出血后72小时内事件构成:年龄(0-4分)、世界神经外科医师联盟评分(0-2.5分)、心肺复苏(2分)、瞳孔散大(1-2分)、中线移位(0.5-1分)、早期恶化(1分)、早期缺血性病灶(2分)。
- 6个月结局分层:SHELTER评分低于5分提示良好结局(mRS 0-2),5至6.5分预测不良结局(mRS 3-5),≥7分与死亡(mRS 6)相关。
- 预测效能:死亡或残疾的曲线下面积为0.899,死亡的曲线下面积为0.877,McFadden伪R²=0.339。
- 研究纳入561例连续aSAH患者,分析出血后72小时内14项潜在预测因子,采用五折交叉验证避免过拟合。
适用人群与场景
- 2014年1月至2022年9月单中心神经血管中心连续收治的561例动脉瘤性蛛网膜下腔出血(aSAH)患者,分析出血后72小时内的临床与影像事件。
诊断标准与关键阈值
- SHELTER评分包含7项:年龄(0-4分)、世界神经外科医师联盟评分(0-2.5分)、心肺复苏(2分)、瞳孔散大(1-2分)、中线移位(0.5-1分)、早期恶化(1分)、早期缺血性病灶(2分)。
- 结局分层:SHELTER评分低于5分提示良好结局(mRS 0-2),5至6.5分预测不良结局(mRS 3-5),≥7分与死亡(mRS 6)相关。
研究设计与关键结果
- 回顾性分析纳入561例连续aSAH患者,分析出血后72小时内14项潜在预测因子,以6个月mRS三分类(0-2分良好、3-5分不良、6分死亡)为结局变量。
- 采用单变量有序回归按显著性排序预测因子,以McFadden伪R²前向选择确定最优预测因子集,行多变量比例优势逻辑回归,排除共线参数,五折交叉验证避免过拟合。
- 最终SHELTER评分包含7项:年龄(0-4分)、世界神经外科医师联盟评分(0-2.5分)、心肺复苏(2分)、瞳孔散大(1-2分)、中线移位(0.5-1分)、早期恶化(1分)、早期缺血性病灶(2分)。
- 模型McFadden伪R²=0.339,死亡或残疾的曲线下面积为0.899,死亡的曲线下面积为0.877。
- SHELTER评分低于5分提示良好结局(mRS 0-2),5至6.5分预测不良结局(mRS 3-5),≥7分与6个月死亡(mRS 6)相关。
证据类型、等级与局限
- 证据类型:回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为SHELTER评分可作为神经重症医生识别aSAH后不良结局患者并指导治疗决策的工具,反映早期脑损伤对aSAH患者总体结局的重要影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite intensive research on preventing and treating vasospasm and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage (aSAH), mortality and morbidity rates remain high. Early brain injury (EBI) has emerged as possibly the major significant factor in aSAH pathophysiology, emphasizing the need to investigate EBI-associated clinical events for improved patient management and decision-making. This study aimed to identify early clinical and radiological events within 72 h after aSAH to develop a conclusive predictive EBI score for clinical practice.
METHODS: This retrospective analysis included 561 consecutive patients with aSAH admitted to our neurovascular center between 01/2014 and 09/2022. Fourteen potential predictors occurring within the initial 72 h after hemorrhage were analyzed. The modified Rankin Scale (mRS) score at 6 months, discretized to three levels (0-2, favorable; 3-5, poor; 6, dead), was used as the outcome variable. Univariate ordinal regression ranked predictors by significance, and forward selection with McFadden's pseudo-R2 determined the optimal set of predictors for multivariate proportional odds logistic regression. Collinear parameters were excluded, and fivefold cross-validation was used to avoid overfitting.
RESULTS: The analysis resulted in the Subarachnoid Hemorrhage Associated Early Brain Injury Outcome Prediction score (SHELTER-score), comprising seven clinical and radiological events: age (0-4 points), World Federation of Neurosurgical Societies (0-2.5 points), cardiopulmonary resuscitation (CPR) (2 points), mydriasis (1-2 points), midline shift (0.5-1 points), early deterioration (1 point), and early ischemic lesion (2 points). McFadden's pseudo-R2 = 0.339, area under the curve for death or disability 0.899 and 0.877 for death. A SHELTER-score below 5 indicated a favorable outcome (mRS 0-2), 5-6.5 predicted a poor outcome (mRS 3-5), and ≥ 7 correlated with death (mRS 6) at 6 months.
CONCLUSIONS: The novel SHELTER-score, incorporating seven clinical and radiological features of EBI, demonstrated strong predictive performance in determining clinical outcomes. This scoring system serves as a valuable tool for neurointensivists to identify patients with poor outcomes and guide treatment decisions, reflecting the great impact of EBI on the overall outcome of patients with aSAH.
参考来源
- Hofmann BB, Donaldson DM, Neyazi M, et al. Clinical Outcome Prediction of Early Brain Injury in Aneurysmal Subarachnoid Hemorrhage: the SHELTER-Score. Neurocrit Care. 2023. PMID: 38030877. doi:10.1007/s12028-023-01879-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。